Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.
Atea Pharmaceuticals Stock Performance
Shares of Atea Pharmaceuticals stock traded down $0.05 on Friday, reaching $3.09. 309,138 shares of the stock were exchanged, compared to its average volume of 313,828. The firm's 50 day moving average is $3.19 and its 200-day moving average is $3.38. Atea Pharmaceuticals has a one year low of $2.75 and a one year high of $4.60. The firm has a market cap of $260.98 million, a PE ratio of -1.49 and a beta of 0.19.
Insider Transactions at Atea Pharmaceuticals
In other news, Director Franklin M. Berger sold 359,606 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the sale, the director now owns 451,897 shares of the company's stock, valued at approximately $1,287,906.45. This represents a 44.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 17.80% of the stock is currently owned by insiders.
About Atea Pharmaceuticals
(
Get Free Report)
Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
Further Reading
Before you consider Atea Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.
While Atea Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
